HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition

Gmyrek, Grzegorz B.; Berube, Amanda N.; Sjoelund, Virginie H.; Carr, Daniel J. J.

doi:10.1038/s41598-022-20180-0

Download PDF

Article
Open access
Published: 23 September 2022

HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition

Grzegorz B. Gmyrek¹,
Amanda N. Berube¹,
Virginie H. Sjoelund² &
…
Daniel J. J. Carr ORCID: orcid.org/0000-0003-1954-2478^1,3

Scientific Reports volume 12, Article number: 15920 (2022) Cite this article

3707 Accesses
1 Citations
1 Altmetric
Metrics details

Subjects

Abstract

Effective experimental prophylactic vaccines against viral pathogens such as herpes simplex virus type 1 (HSV-1) have been shown to protect the host through T and/or B lymphocyte-driven responses. Previously, we found a live-attenuated HSV-1 mutant, 0ΔNLS used as a prophylactic vaccine, provided significant protection against subsequent ocular HSV-1 challenge aligned with a robust neutralizing antibody response. Yet, how the virus mutant elicited the humoral immune response relative to parental virus was unknown. Herein, we present the characterization of B cell subsets in vaccinated mice at times after primary vaccination and following boost compared to the parental virus, termed GFP105. We found that 0∆NLS-vaccinated mice possessed more CD4⁺ follicular helper T (T_FH) cells, germinal B cells and class-switched B cells within the first 7 days post-vaccination. Moreover, 0∆NLS vaccination resulted in an increase in plasmablasts and plasma cells expressing amino-acid transporter CD98 along with an elevated titer of HSV-1-specific antibody compared to GFP105-vaccinated animals. Furthermore, O∆NLS-vaccine-induced CD4⁺ (T_FH) cells produced significantly more IL-21 compared to mice immunized with the parental HSV-1 strain. In contrast, there were no differences in the number of regulatory B cells comparing the two groups of immunized mice. In comparing sera recognition of HSV-1-encoded proteins, it was noted antiserum from GFP105-vaccinated mice immunoprecipitated HSV-1 thymidine kinase (TK) and glycoprotein M (gM) whereas sera from 0∆NLS-immunized mice did not even though both groups of vaccinated mice displayed similar neutralizing antibody titers to HSV-1 and were highly resistant to ocular HSV-1 challenge. Collectively, the results suggest (1) the live-attenuated HSV-1 mutant 0∆NLS elicits a robust B cell response that drives select B cell responses greater than the parental HSV-1 and (2) HSV-1 TK and gM are likely expendable components in efficacy of a humoral response to ocular HSV-1 infection.

Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin

Article Open access 10 April 2024

A guide to vaccinology: from basic principles to new developments

Article 22 December 2020

An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy

Article Open access 12 April 2024

Introduction

Herpes simplex virus type 1 (HSV-1) is a highly transmissible pathogen that establishes a latent infection in which greater than 3.5 billion individuals under the age of 50 are infected worldwide many of which are asymptomatic or present with mild symptoms typically associated with oral mucocutaneous lesions¹. More recently, HSV-1 has established itself as the leading cause of genital HSV infection in developed countries^2,3 and may contribute to the development or severity of Alzheimer’s disease⁴. Whereas there are no licensed vaccines against HSV-1 to date, there are numerous experimental prophylactic vaccine candidates including live-attenuated, recombinant, subunit cocktail, and epitope-based vaccines^5,6,7,8,9,10. Most, if not all, of these vaccines elicit some form of adaptive immune response with the generation of memory T and B lymphocytes. Moreover, the attenuated or recombinant virus vaccines are designed to reduce or eliminate the establishment of latency in comparison to their parental, wild type counterparts which, in turn, would reduce or eliminate the possibility of reactivation.

The importance of the humoral response is unquestionable in defenses against viral infections including measles, rubella, and chicken pox viruses as resistance often depends on antibody levels¹¹. B cells are central to the humoral response differentiating into antibody-secreting plasma cells. Indeed, in patients taking rituximab, an anti-CD20 monoclonal antibody which depletes peripheral B-cells and causes subsequent hypogammaglobulinemia, numerous viral infections are frequently reported^12,13. Experimental studies have reported B-cell-deficient mice are less efficient in controlling HSV-1 infection with a higher incidence of encephalomyelitis and an increase in the establishment of viral latency^14,15,16. This outcome may be influenced by the role of antigen presentation by B cells. Specifically, in HSV-1-infected B cell deficient mice, the number of CD4⁺ T cells that differentiate into IFN-γ-expressing CD4⁺ effector T cells are diminished whereas there are no significant changes in CD8⁺ T cell or NK cell populations¹⁷. Thus, B lymphocytes are a critical cell population in antibody production and antigen presentation that along with T cell-driven antibody class switching and affinity maturation in the germinal centers^18,19 are instrumental in viral surveillance.

Draining lymph nodes are critical to the development of anti-viral immunity including T-dependent B cell class switching to IgG²⁰. During the innate immune response to viral pathogens within the lymph node, type I IFNs are often expressed and facilitate the development of a Th1 response^21,22 and maintain lymphatic vessel expression for afferent delivery of antigen²³. However, type I IFN can have detrimental outcomes to the B cell response as they can drive terminal B lymphocyte differentiation to short-lived plasma cells depleting the anti-viral B cell population through the combination of the local activation of myeloid cells and the expression of TNF-α²⁴. Thus, a fine balance between the anti-viral innate defenses and B and T cell activation in response to virus infection must be maintained to optimize the adaptive immune response including the generation of memory T and B lymphocytes.

We have begun to characterize the host immune response to a live, attenuated HSV-1, termed HSV-1 0∆NLS, used as a prophylactic vaccine against ocular HSV-1 challenge. This mutant virus lacks the nuclear localization signal of immediate early gene of infected cell protein 0 (ICP0) such that it is highly sensitive to the effects of type I IFN but remains highly immunogenic in vivo²⁵. The efficacy has been linked to the humoral immune response as well as T cells that contribute to B cell help and CD8⁺ effector T cell activation and function^5,26. In the present study, the B lymphocyte profile in the draining lymph nodes of HSV-1 0∆NLS vaccinated mice was conducted following the initial vaccine and boost. To determine if differences existed in the B cell response in vaccinating mice with an attenuated virus versus a fully competent virus, we compared the B cell profile of the HSV-1 0∆NLS to the parental KOS counterpart, GFP105. Following the initial vaccination, there was a significant increase in the number of CD4⁺ T follicular helper (T_FH) and B cell subsets residing in the spleen and draining (popliteal) lymph node of the 0∆NLS vaccinated mice compared to the GFP105-vaccinated group. However, there was no change in antibody neutralization titers to HSV-1 following the initial vaccination or boost comparing the two vaccinated groups of mice. Likewise, there was no difference in efficacy in terms of preservation of the visual axis and lack of corneal pathology. However, two HSV-1 encoded proteins were not recognized by sera from 0∆NLS vaccinated mice including glycoprotein M and thymidine kinase. Furthermore, there was a significant reduction in recognition of glycoprotein C by 0∆NLS sera compared to sera from the parental virus vaccinated group in terms of peptide hits. Consequently, while mice vaccinated with the 0∆NLS attenuated virus display equivalent resistance to subsequent ocular HSV-1 challenge compared with GFP105-vaccinated animals, there were noted differences in the humoral immune response such that we would conclude glycoprotein M and thymidine kinase are not necessary as antibody targets for prophylactic vaccine efficacy against ocular HSV-1 challenge.

Results

Primary Vaccination with HSV-1 0∆NLS increases the number of T_FH cells and enhanced production of IL-21 that correlates with an increase in germinal center B cell formation

T helper (T_H) cells and dendritic cells play a critical role in the proliferation and differentiation of plasma cells and memory B cells initially taking place in distinct areas of the lymph nodes following tissue antigen (virus) exposure²⁷. B cell proliferation within the follicles of the lymph node give rise to germinal centers, a specialized microanatomical region that provides an environment conducive to the selection of high-affinity antibody expressing B cells^18,28. CD4⁺ T follicular helper (T_FH) cells recruited to these sites through expression of CXCR5 facilitate germinal center (GC) B cell formation through interleukin (IL)-21 secretion^29,30. To initiate our analysis of virus exposure to induction of B cell responses, we assessed whether vaccination of mice with HSV-1 0∆NLS resulted in changes in CD4⁺ T_FH cell defined as CD45⁺CD4⁺PD1⁺CXCR5⁺Bcl-6⁺ (Fig. 1A) and GC B cell defined as CD45⁺CD19⁺GL7⁺CD95⁺ (Fig. 1B) numbers compared to mice vaccinated with parental HSV-1 (GFP105) in the draining (popliteal) lymph node (PLN) at days 7 and 21 and spleen at day 21 post footpad administration. The results showed significantly more CD4⁺ T_FH cells and GC B cells in 0∆NLS vaccinated mice compared to those immunized with the parental HSV-1 GFP105 at the day 7 time point in the PLN, and day 21 post immunization in the spleen (Fig. 1C, D, and Fig. 1E, F). These results paralleled frequency findings as well. Specifically, a greater percentage of CD4⁺ T_FH and GC B cells were found in the PLN of 0∆NLS vaccinated mice at day 7 (13.09 ± 0.85% and 5.44 ± 0.71% respectively, *p < 0.05) compared to that in the PLN of GFP105 immunized animals (9.54 ± 1.02% and 3.46 ± 0.3%). Likewise, a greater percentage of CD4⁺ T_FH and GC B cells were found in the PLN of 0∆NLS vaccinated mice at day 21 (13.24 ± 1.01% and 2.71 ± 0.31% respectively, *p < 0.05) compared to that in the PLN of GFP105 immunized animals (9.56 ± 0.97% and 1.33 ± 0.23%). Consistent with these findings, the percentage of CD4⁺ T_FH cells expressing IL-21 from the PLN (Fig. 1G) was elevated in HSV-1 0∆NLS vaccinated mice compared to mice immunized with HSV-1 GFP105 at day 7 post immunization (Fig. 1H). This result equated to nearly twice as many IL-21-expressing cells from the PLN of HSV-1 0∆NLS vaccinated mice (58 ± 8) versus GFP105 immunized animals (31 ± 4). Likewise, IL-21 content in the PLN of HSV-1 0∆NLS vaccinated animals was significantly higher compared to HSV-1 GFP105 immunized mice (Fig. 1I). No differences were noted in the total CD4⁺ T cell count in the PLN or spleen comparing HSV-1 ∆NLS to GFP105 vaccinated animals (data not shown). Collectively, the results suggest HSV-1 ∆NLS promotes B cell expansion in the GC as a result of a specific increase in the number of IL-21 producing CD4⁺ T_FH cells in the PLN.

Vaccination of mice with HSV-1 0ΔNLS results in an increase in the number of class-switched B cells associated with an increase in the titer of anti-HSV-1 antigen-specific IgG2b compared to HSV-1 GFP105 immunized animals

Production of high affinity antigen-specific immunoglobulin as a result of somatic hypermutation and class switching often leads to efficient eradication of pathogens through neutralization and/or antibody-dependent cellular cytotoxicity. As a means to further study the dynamics of B cell activation following exposure to HSV-1, we next investigated class-switching defined by CD19⁺IgD^-IgM^- B cells (Fig. 2A) in the PLN at day 7 or day 21 in the spleen post-vaccination. HSV-1 0∆NLS vaccinated mice were found to possess significantly more CD19⁺IgD^-IgM^- B cells in the PLN and spleen at day 7 and day 21 post immunization, respectively (Fig. 2B, C). These results correlate with higher anti-HSV-1 IgG1 (Fig. 2D) and IgG2b (Fig. 2E) serum titers at day 21 post infection, although significance was noted only in case of anti-HSV-1 IgG2b (Fig. 2E). In contrast, there was no difference in the antibody neutralization titer to HSV-1 comparing mice vaccinated with 0∆NLS versus parental GFP105 (Fig. 2F). Thus, whereas 0∆NLS vaccinated mice display an elevation in class-switching that corresponds to increased anti-HSV-1 IgG2b titers, such results did not equate to an equivalent difference in antibody neutralization titers compared to GFP105 vaccinated mice suggesting a threshold in the level of anti-HSV-1 antibody titers has been reached in both vaccinated groups relative to virus neutralization. Nevertheless, the data does demonstrate an attenuated virus highly sensitive to type I IFN elicits a robust B cell antibody response that is equivalent to or greater than the non-attenuated parental virus when used as an immunogen to protect the host against ocular HSV-1 infection.

HSV-1 0∆NLS vaccination induces higher number of plasmablasts and plasma cells expressing CD98

Antibody is produced by terminally differentiated B cells known as plasmablasts (PBs), which later give rise to plasma cells (PCs)³¹. The expression of the amino acid transporter CD98 has been shown to correlate with metabolic activity, longevity, antibody production, B cell proliferation and plasma cells formation^32,33,34. In addition, the production of antibodies by long-lived plasma cells (LLPC) correlates with higher expression of CD98 as compared with short-lived plasma cells (SLPC)³⁴. Given that the total number of PBs and PCs was not affected by vaccination (data not shown), we addressed how vaccination affect PBs and PCs in the context of their expression of CD98 at day 7 in the PLN and day 21 in the spleen post-vaccination. The expression of CD98 was found to be higher on PBs (CD19⁺CD138⁺, Fig. 3A) and PCs (B220^lowCD138⁺, Fig. 3B) in 0∆NLS-vaccinated mice resulting in significantly more of these cells in the spleen at day 21 post-vaccination (Fig. 3C, D respectively) but not in the lymph node at day 7 post-vaccination (Fig. 3E, F respectively). These results were also found to be true assessing frequency with a significantly greater percentage of PCs in the spleen of 0∆NLS-immunized mice at day 21 (35.29 ± 2.01%, *p < 0.05) compared to that found in the GFP105 immunized mice (19.66 ± 1.64%) but not that found in the PLN of 0∆NLS immunized mice at day 7 (6.19 ± 0.67%) compared to GFP105 vaccinated animals (4.66 ± 0.34%).

While most B cell subsets function are related to antibody production, cytokine secretion or antigen presentation, regulatory B cells (Breg) are known to possess immunosuppressive characteristics³⁵. We characterized two Breg cell populations (Fig. 3G) that might have regulatory function including “classic” Breg cells (CD19+CD21+CD23+CD5+CD1d+) and a B cell population resembling marginal zone B cells (CD19+CD21+CD23-CD5+CD1d-)^36,37. The data show both Breg cell subsets were modest in number in the draining lymph nodes at day 7 post-vaccination (Fig. 3H, I). However, by day 21 post-vaccination, both Breg cell populations were readily detectable in the spleen (Fig. 3J, K). Yet, at both time points evaluated there was no differences in the number of Breg cells residing in the PLN or spleen of GFP105 vs 0∆NLS-vaccinated animals suggesting that changes in PB and PC numbers were not reflected by Breg cell numbers in either the spleen or PLN of vaccinated mice. In summary, HSV-1 0∆NLS vaccine-induced animals develop a favorable B cell differentiation to PBs and PCs expressing CD98 over time evident by an increased number in the spleen. Such results are not apparent early on following vaccination in the PLN.

Class-switched and germinal center B cell numbers and IFN-γ-secreting, HSV-1 gB-specific CD8⁺ T cell numbers remain elevated post-vaccination boost in the spleen of mice immunized with the 0∆NLS vs GFP105 vaccine

Following primary vaccination, mice immunized with the 0∆NLS vaccine showed an increase in the number of GC B cells and class-switched B cells in the spleen compared to animals immunized with GFP105 21 days post-vaccination. To determine if this relationship changed following re-exposure to antigen in the form of a vaccine boost, mice vaccinated with 0∆NLS and GFP105 were boosted 21 days following the initial vaccination. Thirty days post-vaccine boost, the spleens of mice were evaluated for GC and class-switched B cell numbers. Consistent with the results following primary immunization, animals boosted with the 0∆NLS vaccine possessed significantly more GC (Fig. 4A) and class-switched (Fig. 4B) B cells as well as IgG1-secreting (Fig. 4C) B cells compared with animals boosted with GFP105. However, there was no difference in neutralizing antibody titers of sera obtained from GFP105- versus 0∆NLS-boosted animals (Fig. 4D).

Previously, we reported 0∆NLS-vaccinated mice displayed more functional HSV-1 gB-specific CD8⁺ T cells 7 days post-vaccination compared to mice immunized with GFP105³⁸. Similar to the experimental design above, we wished to determine whether this relationship held following the booster immunization, mice vaccinated with GFP105 or 0∆NLS were evaluated for IFN-γ-secreting, HSV-1 gB-specific CD8⁺ T cells at 21 days post-primary immunization and 30 days post-boost. Similar to the results described for splenic B cells, there were nearly two times as many IFN-γ-secreting CD8⁺ T cells from the spleen of 0∆NLS-vaccinated mice compared to those immunized with GFP105 at the 21-day time point (Fig. 4E). Whereas the re-exposure to antigen in the form of a boost expanded this population in both vaccinated groups of mice 30-days post-boost, a significant increase in the number of IFN-γ-secreting, HSV-1 gB-specific CD8⁺ T cells from the 0∆NLS-vaccinated animals was noted (Fig. 4E). Therefore, the effect of 0∆NLS vaccination are not restricted to B cell populations but are found to influence functional CD8⁺ T cells as well.

Visual axis remains intact in vaccinated mice following challenge with HSV-1

In mice, acute ocular HSV-1 infection often results in cornea pathology including denervation^39,40, opacity as a result of collagen fiber disruption⁴¹, inflammatory hypoxia⁴², local changes in substance P levels⁴³, and products of infiltrating leukocytes⁴⁴, hemangiogenesis⁴⁵, lymphangiogenesis⁴⁶, and edema⁴⁷ leading to blindness or significant vision loss⁴⁸. In previous work, we found a clear association with vaccine efficacy and preservation of the visual axis in terms of architecture, cornea integrity, and vision performance²⁶. Specifically, HSV-1-elicited cornea denervation parallels the loss of mechanosensory function during acute infection⁴⁰. Likewise, corneal thickness and reduction in vision acuity have been noted following HSV-1 cornea infection²⁶. To determine whether there was any difference in efficacy of vaccinated mice to ocular HSV-1 challenge, GFP105- and 0∆NLS-vaccinated mice were infected with HSV-1 30 days post boost and evaluated for changes in the visual axis at 15 days post infection, a time when pathological changes within the cornea are evident and quantifiable⁴⁸. We found no differences in the blink response associated with corneal denervation (Fig. 5A), edema (Fig. 5B), visual acuity (Fig. 5C), or neovascularization (Fig. 5D) comparing the vaccinated mice prior to and following infection. In the case of neovascularization (Fig. 5D), both GFP105- and 0∆NLS-vaccinated animals showed no corneal neovascularization in comparison to HSV-1-infected naive, non-vaccinated mouse underscoring the robust nature of protection in generating a protective immune response using the attenuated HSV-1 0∆NLS. Thus, GFP105- and 0∆NLS-vaccinated animals show no loss in visual function or pathology suggesting equivalent degrees of efficacy against ocular HSV-1 infection.

Some HSV-1 encoded proteins are recognized by sera from GFP105- but not 0∆NLS-vaccinated mice

Previous studies by our group and others have reported on the importance of humoral (antibody) immunity against HSV infection^26,49. Although we found no difference in the neutralizing antibody titer comparing GFP105- to 0∆NLS-vaccinated animals, there may be differences in the recognition pattern of antibodies to HSV-1-encoded proteins comparing the profiles generated from GFP105 and 0∆NLS sera immunoprecipitated samples. Therefore, we utilized mass spectrometry to identify virus-encoded proteins recognized by antiserum from GFP105- and 0∆NLS-vaccinated animals. The results show a total of 44 HSV-1-encoded proteins were identified from immunoprecipitated samples using GFP105 sera compared to 42 proteins from 0∆NLS sera. Two proteins uniquely precipitated by GFP105 sera included unique long (UL)10/glycoprotein (g)M and UL23/thymidine kinase (TK) (Fig. 6). Furthermore, two proteins immunoprecipitated by the GFP105 sera were found to have significantly higher peptide hits compared to that immunoprecipitated by 0∆NLS sera including UL50/dUTPase and UL44/gC (Fig. 6). No other HSV-1-encoded proteins identified by relative abundance of peptide hits were found to be different between GFP105 and 0∆NLS immunoprecipitated samples (data not shown). Of note, antibody recognition of proteins previously found to correlate with preservation of the visual axis including UL19/virion protein (VP)5, UL29/infected cell protein (ICP)8, UL27/gB, UL40/ribonuclease reductase subunit (RR)2, unique short (Us)6/gD, Us8/gE, UL1/gL, UL48/VP16, and UL12/alkaline nuclease (AN)⁵⁰ were found to be recognized by antiserum from GFP105- and 0∆NLS-vaccinated mice suggesting these proteins may be critical in immune recognition to control acute ocular HSV-1 infection. We interpret the results to also suggest HSV-1-encoded TK and/or gM are not critical viral proteins to mount an antibody response to since the lack of recognition by antiserum from 0∆NLS-vaccinated mice did not lessen preservation of the visual axis.

Discussion

There are many extrinsic and intrinsic factors that influence B cell survival, proliferation, differentiation, isotype switching and immunoglobulin secretion^{51,52,53,54,55}. Cytokines are one set of factors that have a critical role in the regulation of B cell activation. For example, IFN-γ induces B cell proliferation as well as increases in IgG2 production^56,57. Type I IFN augments B cell activation as well as differentiation to antibody-secreting cells and B cell receptor sensitivity^58,59. Still, another cytokine IL-12, has been shown to promote differentiation of naive B cells into plasma cells⁶⁰. In a previous study, we reported following initial vaccination with HSV-1 0∆NLS, an elevation in type I IFN and IL-12 production by cells was noted which drove an increase in IFN-γ-expressing CD8⁺ T cells in comparison to mice vaccinated with GFP105³⁸. Thus, using the same vaccination model, changes in B cell subset formation may be linked to an altered cytokine microenvironment.

CD4⁺ T_FH cells play an important role in the regulation of T-cell dependent, B cell activation and differentiation. They are positioned within GC where they support the GC B cell activation, specifically B cell proliferation, class-switch recombination and differentiation of B cells into plasma cells^30,61,62. In the present study, we report an increased number of CD4⁺ T_FH cells along with increased secretion of IL-21 by these cells. The importance of IL-21 in the regulation of B cell function has been described using IL-21 receptor-deficient mice. These mice were found to possess a compromised humoral immune response to T cell-dependent antigens. Specifically, GC B cells were found to be severely impaired resulting in an attenuated B cell proliferation response with a deficiency in plasma cell differentiation^63,64,65,66. Similar to the current results, it was reported vaccination with another live-attenuated HSV-1 virus termed VC2 resulted in increased proliferation of CD4⁺ T_FH cells that correlated with robust antibody production and GC B cell activation⁶⁷. Taken together, these studies underscore the strong influence of CD4⁺ T_FH production of IL-21 on GC B cell responses relative to PB and PC numbers as well as increased anti-HSV-1 antibody levels. While the mechanism that drives enhanced GC B cell activation is currently unknown, it is tempting to speculate it may involve levels of lymphotoxin generated by localized T cells as a previous study reported a loss in T_FH cells and impaired antibody response to HSV-1 using a lymphotoxin β receptor deficient mouse model⁶⁸.

Our previous studies described changes in cell metabolism might be linked to effector function of CD8⁺ T cells. Relative to B lymphocytes, the activation and differentiation states of B cells may depend on their metabolism^69,70. Long-lived plasma cells expressing amino-acid transporter CD98 utilize 90% of their cellular glucose not to generate ATP and metabolites but rather, for glycosylation of secreted antibodies³². The present study found mice vaccinated with 0ΔNLS possessed more PB and PC expressing CD98 in the spleen 3 weeks after primary vaccination in comparison to mice vaccinated with GFP105. Whether the 0∆NLS vaccination altered cell metabolism in the naive B cells driving proliferation and differentiation is currently unknown. CD98 deficiency has been reported to reduce B cell proliferation, PC formation, and antibody production; however, B cell proliferation does not depend on amino-acid transport function but rather CD98 supports integrin-dependent proliferation of B cells³⁴. Further studies are needed to reveal whether an interconnected network of genes and metabolic pathways correlate with PC function after vaccination with HSV-1 0ΔNLS.

In addition to characterizing the initial B cell response following vaccination with 0∆NLS and GFP105, we also evaluated the response following vaccine boost 21 days post primary vaccination. Similar results in the B cell responses were noted. Furthermore, vaccinated mice retained and preserved their visual axis whether immunized with HSV-1 GFP105 or 0∆NLS. These results are critical for two reasons: (1) the attenuated HSV-1 0∆NLS elicits the same if not better humoral immune response as the fully virulent parental virus used as vaccines and (2) the immune response provides sufficient protection to retain the integrity and performance of the visual axis. Most experimental studies do not go into depth in terms of evaluating the cornea and how changes to its architecture may hinder the rodent’s peripheral vision. Denervation of the cornea in response to HSV-1 infection is a common response in mice^39,40. Likewise, inflammation of the cornea as a result of HSV-1 infection in experimental animal models often leads to edema and neovascularization^23,71. The culmination of these and other events can lead to a loss of peripheral vision as measured by optomotor kinetic tracking or OKT²⁶. In the current study, the evaluation of these parameters in comparing HSV-1 0∆NLS to GFP105 demonstrates that the attenuated virus delivers the same degree of protection at a reduced risk of establishing latency compared to the parental virus²⁵. Such results are consistent with equivalent neutralizing antibody titers to HSV-1 which we have previously reported is an essential component of a protective immune response associated with the HSV-1 0∆NLS vaccine⁵. However, upon evaluation of viral proteins recognized by antiserum from vaccinated animals, there were noted deficiencies in the recognition of some viral-encoded proteins in the 0∆NLS-vaccinated group. Specifically, 0∆NLS-induced antiserum did not immunoprecipitate HSV-1 gM or TK where sera from GFP105 immunized mice did. Moreover, recognition of HSV-1 UL50- and gC-encoded proteins based on peptide hits was reduced in the immunoprecipitated samples from 0∆NLS sera pulldowns. However, other virus-encoded proteins previously found to correlate with vaccine efficacy including VP5, ICP8, gB, RR2, gD, gE, gL, VP16, and AN⁵⁰ were recognized by GFP105 and 0∆NLS antiserum. Thus, we conclude these proteins are important in the recognition by antibody to suppress virus replication and spread from the eye to the nervous system as well as prevent cornea pathology and preserve the function of the visual axis. In conclusion, the humoral immune response elicited by prophylactic vaccines is a critical component of providing resistance to subsequent HSV challenge reinforced in this study and others^49,72. In the human patient, it has been noted HSV-1-specific memory B cells including class-switched memory B cells are correlated with asymptomatic HSV-1 seropositive individuals in comparison to symptomatic HSV-1 seropositive patients underscoring the likely contribution of humoral immunity in HSV-1 surveillance in the latent-infected human host⁷³.

Materials and methods

Mice

Six-to-eight-week-old male and female C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME) and housed under specific-pathogen free conditions in the animal vivarium at the Dean McGee Eye Institute. All procedures described under the methods section were approved by the University of Oklahoma Health Sciences Center animal care and use committee (protocol # 19–060 ACHIX). This study was carried out in compliance with the ARRIVE Essential 10 Guidelines.

Mice infection/vaccination

Animals were vaccinated with parental GFP105 or live-attenuated 0ΔNLS HSV-1 derived from KOS strain⁵. Briefly, mice were footpad injected with 1 × 10⁵ PFU of GFP105 or HSV-1 0ΔNLS in 10ul of PBS. HSV-1 GFP105 has a GFP coding sequence on the immediate early ICP0 gene between codons 104 and 105 on exon 2 under a cytomegalovirus promoter, whereas HSV-1 0ΔNLS lacks the nuclear localization signal (NLS) motif, R-P-R-K-R-R, encoded by amino acids 501 to 508 on exon 3 on the GFP105 background. For tissue collection, mice were anesthetized by i.p. injection of ketamine and xylazine and blood collected prior to exsanguination. Alternatively, at day 21 post primary footpad immunization, anesthetized mice were immunized a second time in the ipsilateral flank (ID) with the same amount of virus described above. Thirty days post-booster, mice were anesthetized by i.p. injection of ketamine and xylazine and blood collected prior to exsanguination. The PLN and spleen were processed, and cells labeled as described below. Serum was fractionated using Microtainer serum separator tubes (Becton Dickinson, Franklin Lakes, NJ) and stored at −80 °C until used in serum immunoassays.

IL-21 cytokine measurement

IL-21 cytokine content in tissue was performed with a commercially available pre-coated IL-21 ELISA kit plate (Thermo Fisher Scientific, Waltham, MA USA). PLN harvested at day 7 post infection were placed into 1.5 mL snap-capped Eppendorf tubes (Advanced Bullet Blender, Troy, NY) containing RIPA buffer (50 mM Tris–HCl, 1% NP-40, 150 mM NaCl, 1 mM EDTA, and protease and phosphatase inhibitors) and then homogenized using a Bullet Blender Storm 24 (Advanced Bullet Blender). The samples were then centrifuged (10,000 × g, 1 min), and cell-free lysates were collected and frozen at −80 °C until analyzed in the IL-21 ELISA assay. Intracellular cytokine staining within CD4⁺ T_FH cells was performed using a commercially available anti-mouse IL-21 antibody conjugated with PE (R&D Systems, Minneapolis, MN USA). Specifically, the lymph nodes collected at day 7 post-vaccination were passed through a 40 µm filter cell strainer (Midsci, St. Louis, MO) resulting in single-cell suspensions. Next, 3 × 10⁶ cells were stimulated with phorbol 12-myristate 13-acetate (PMA, 100 nM) and ionomycin (1ug/ml) for 6 h in the presence of brefeldin A (GolgiPlug, BD Biosciences). After the incubation period, cells were washed and stained with an antibody cocktail (containing anti-mouse CD45 conjugated with PerCP-Cy5.5, anti-mouse CD3 conjugated with PE-Cy7, anti-mouse CD4 conjugated with APC-Cy7, anti-mouse CXCR5 conjugated with BV421, and anti-mouse PD-1 conjugated with FITC) for 15 min at room temperature. Next, the cells were fixed, permeabilized, and stained with anti-mouse IL-21 conjugated with PE. The samples were then acquired with a MacsQuant flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany) and analyzed with FlowJo software (BD Biosciences, Medford, OR).

Isotype ELISA

IgG1 and IgG2b-specific HSV-1 antibody titers were measured by ELISA. Briefly, 96-well microtiter plates were coated with purified HSV-1 virions in carbonate buffer (pH 9.6) and incubated overnight at 37 °C. The plates were washed with PBS-polyoxyethylene (20) sorbitan monolaurate (Tween20, ThermoFisher Scientific, Waltham, MA) to remove excess antigen and serial dilutions of mouse sera were added to the wells followed by incubation at room temperature for 2 h. Next, the plates were washed with PBS-Tween and incubated with alkaline phosphatase-conjugated anti-mouse IgG1, or IgG2b detection antibodies (1:2000 dilution; Southern Biotechnology, Birmingham, AL) for 2 h at room temperature. Finally, the plates were washed with PBS-Tween and incubated with para-nitrophenyl phosphate substrate for 18 h at 37 °C. The optical density at 450 nm was measured using a Clariostar microplate reader (BMG Labtech, Ortenberg, Germany) with background correction at 540 nm.

Antibody neutralization assay

Antibody neutralization assays were performed by exposing the confluent monolayers (50,000 cells/well of 96-well microtiter plate) of Vero cells (American Type Culture Collection, Manassas, VA) to 10,000 PFU HSV-1 (McKrae strain) in the presence or absence of serial dilutions of serum in the presence of guinea pig complement (Rockland Immunochemicals, Limerick, PA) for 2 h. Next, the serum dilutions were decanted, and Vero cells were incubated in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1 × antibiotic/antimycotic, and 10 μg/ml gentamicin (Gibco Life Technologies, Grand Island, NY) for 24 h. Neutralization titers were reported as the reciprocal serum dilution at which a 50% reduction in cytopathic effect is observed.

Flow cytometry

CD4 T_FH cells and B cell subpopulation characterization was assessed by flow cytometry at day 7 and day 21 post primary footpad immunization or 30 days post-booster. Briefly, spleens were passed through a 40 µm filter cell strainer (Midsci) resulting in single-cell suspensions followed by treatment with multispecies red cell lysis buffer (Thermo Fisher Scientific, Waltham, MA) for red cell removal. Next, cells were washed and resuspended in PBS supplemented with 2% FBS (herein referred to as staining buffer or SB). PLN were harvested at the indicated time points and processed identical to spleens. One million spleen- or PLN-derived cells were resuspended in 100ul of SB and stained for the following cell population: follicular CD4⁺ T cells (CD45⁺CD3⁺CD4⁺PD-1⁺CXCR5⁺Bcl-6⁺), germinal B cells (CD45⁺CD19⁺GL-7⁺CD95⁺), plasma cells (CD45⁺B220^lowCD138⁺), plasmablasts (CD19⁺CD138⁺) class-switched B cells (CD45⁺CD19⁺IgM^-IgD^-), subsets and effectors of regulatory B cells (Bregs): marginal zone B cells (CD45⁺CD19⁺CD23⁺CD21^-) and B10 (CD45⁺CD19⁺CD5⁺CD1d^high). The samples with stained cells were acquired with MacsQuant flow cytometer (Miltenyi Biotec) or spectral flow cytometer Aurora (Cytek Biosciences, Fremont, CA) as described previously³⁸. For assessment of HSV-1 gB-specific CD8⁺ T cell function, we utilized a procedure previously described by our group⁷⁴. Acquired samples were exported as FCS files and further analyzed using FlowJo software version 10.8.1 (BD Biosciences, Medford, OR).

ELISPOT assay for evaluation IFN-γ

ELISPOT for IFN-γ was described previously³⁸. Briefly, 96-plate with immobilon-P membrane were coated overnight with primary IFN-γ Ab (BD Biosciences). Cells isolated from spleen of mice harvested at day 21 and at day 30 after boost, were plated at concentration 5 × 10⁵ cells per well followed by overnight re-stimulation with HSV-1 derived gB peptide, SSIEFARL (10 ug/ml). The plate was developed as described previously³⁸.

Visual axis assessment

Mechanosensory function, cornea edema and neovascularization, and visual acuity evaluations were performed by esthesiometry, optical coherence tomography, confocal microscopy, and optokinetic tracking responses as previously described⁷⁵.

Immunoprecipitation of HSV-1 proteins and identification by mass spectrometry

Sera obtained from GFP105- and 0∆NLS-vaccinated mice collected 30 days post-boost were used to immunoprecipitate viral proteins from HSV-1-infected Vero cell lysates as previously described⁵⁰. Tryptic digestion of isolated proteins and mass spectrometry analysis was performed as previously described⁵⁰.

Statistical analysis

Statistical analysis was performed using GraphPad Prism (version 9.3.0). Data were shown as means ± standard error of the mean (SEM). Each figure legend describes the statistical test used for data analysis. Differences comparing GFP105- to 0∆NLS-vaccinated mice were considered significant with a p value < 0.05.

Data availability

The data sets generated and analyzed for this study are available from the corresponding author upon reasonable request.

References

Looker, K. J. et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS ONE 10, e0140765 (2015).
Article PubMed PubMed Central Google Scholar
Chemaitelly, H., Nagelkerke, N., Omori, R. & Abu-Raddad, L. J. Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. PLoS ONE 14, e0214151 (2019).
Article CAS PubMed PubMed Central Google Scholar
Ayoub, H. H., Chemaitelly, H. & Abu-Raddad, L. J. Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA: Model-based predictions. BMC Med. 17, 57 (2019).
Article PubMed PubMed Central Google Scholar
Itzhaki, R. F. Herpes simplex virus type 1 and Alzheimer’s disease: possible mechanisms and signposts. FASEB J.: Official Publication of the Federation of American Societies for Experimental Biology 31, 3216–3226 (2017).
Article CAS Google Scholar
Royer, D. J. et al. A highly efficacious herpes simplex virus 1 vaccine blocks viral pathogenesis and prevents corneal immunopathology via humoral immunity. J. Virol. 90, 5514–5529 (2016).
Article CAS PubMed PubMed Central Google Scholar
Bloom, D. C., Tran, R. K., Feller, J. & Voellmy, R. Immunization by replication-competent controlled herpesvirus vectors. J. Virol 92, e00616-18 (2018).
Article CAS PubMed PubMed Central Google Scholar
Srivastava, R. et al. Therapeutic mucosal vaccination of herpes simplex virus 2-infected guinea pigs with ribonucleotide reductase 2 (RR2) protein boosts antiviral neutralizing antibodies and local tissue-resident CD4(+) and CD8(+) TRM cells associated with protection against recurrent genital herpes. J. Virol. 93, e02309-18 (2019).
Article CAS PubMed PubMed Central Google Scholar
Naidu, S. K. et al. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. PLoS ONE 15, e0228252 (2020).
Article PubMed PubMed Central Google Scholar
Patel, C. D. et al. Trivalent glycoprotein subunit vaccine prevents neonatal herpes simplex virus mortality and morbidity. J. Virol. 94, e02163-19 (2020).
Article CAS PubMed PubMed Central Google Scholar
Ramsey, N. L. M. et al. A single-cycle glycoprotein D deletion viral vaccine candidate, ΔgD-2, elicits polyfunctional antibodies that protect against ocular herpes simplex virus. J. Virol. 94, e00335-20 (2020).
Article CAS PubMed PubMed Central Google Scholar
Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705–742 (2013).
Article CAS PubMed Google Scholar
Kado, R., Sanders, G. & McCune, W. J. Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy. Curr. Opin. Rheumatol. 29, 228–233 (2017).
Article CAS PubMed Google Scholar
Aksoy, S. et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 48, 1307–1312 (2007).
Article CAS PubMed Google Scholar
Kapoor, A. K., Nash, A. A. & Wildy, P. Pathogenesis of herpes simplex virus in B cell-suppressed mice: The relative roles of cell-mediated and humoral immunity. J. Gen. Virol. 61(Pt l), 127–131 (1982).
Article PubMed Google Scholar
Simmons, A. & Nash, A. A. Effect of B cell suppression on primary infection and reinfection of mice with herpes simplex virus. J. Infect. Dis. 155, 649–654 (1987).
Article CAS PubMed Google Scholar
Beland, J. L., Sobel, R. A., Adler, H., Del-Pan, N. C. & Rimm, I. J. B cell-deficient mice have increased susceptibility to HSV-1 encephalomyelitis and mortality. J. Neuroimmunol. 94, 122–126 (1999).
Article CAS PubMed Google Scholar
Deshpande, S. P., Kumaraguru, U. & Rouse, B. T. Dual role of B cells in mediating innate and acquired immunity to herpes simplex virus infections. Cell Immunol. 202, 79–87 (2000).
Article CAS PubMed Google Scholar
Mesin, L., Ersching, J. & Victora, G. D. Germinal center B cell dynamics. Immunity 45, 471–482 (2016).
Article CAS PubMed PubMed Central Google Scholar
Bannard, O. & Cyster, J. G. Germinal centers: Programmed for affinity maturation and antibody diversification. Curr. Opin. Immunol. 45, 21–30 (2017).
Article CAS PubMed Google Scholar
Karrer, U. et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice. J. Exp. Med. 185, 2157–2170 (1997).
Article CAS PubMed PubMed Central Google Scholar
Brinkmann, V., Geiger, T., Alkan, S. & Heusser, C. H. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J. Exp. Med. 178, 1655–1663 (1993).
Article CAS PubMed Google Scholar
Farrar, J. D. et al. Selective loss of type I interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2. Nat. Immunol. 1, 65–69 (2000).
Article CAS PubMed Google Scholar
Bryant-Hudson, K. M. et al. HSV-1 targets lymphatic vessels in the eye and draining lymph node of mice leading to edema in the absence of a functional type I interferon response. Am. J. Pathol. 183, 1233–1242 (2013).
Article CAS PubMed PubMed Central Google Scholar
Fallet, B. et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci. Immunol. 1, e6817 (2016).
Article Google Scholar
Royer, D. J., Carr, M. M., Chucair-Elliott, A. J., Halford, W. P. & Carr, D. J. Impact of type I interferon on the safety and immunogenicity of an experimental live-attenuated herpes simplex virus 1 vaccine in mice. J. virol. 91, e02342-16 (2017).
Article PubMed PubMed Central Google Scholar
Royer, D. J. et al. Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection. Mucosal Immunol. 12, 827–839 (2019).
Article CAS PubMed PubMed Central Google Scholar
Pereira, J. P., Kelly, L. M. & Cyster, J. G. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol 22, 413–419 (2010).
Article CAS PubMed PubMed Central Google Scholar
De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. Nat. Rev. Immunol. 15, 137–148 (2015).
Article PubMed PubMed Central Google Scholar
Hale, J. S. et al. Distinct memory CD4+ T cells with commitment to T follicular helper- and T helper 1-cell lineages are generated after acute viral infection. Immunity 38, 805–817 (2013).
Article CAS PubMed PubMed Central Google Scholar
Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular helper T Cells. Annu. Rev. Immunol. 34, 335–368 (2016).
Article CAS PubMed Google Scholar
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160–171 (2015).
Article CAS PubMed Google Scholar
Lam, W. Y. et al. Mitochondrial pyruvate import promotes long-term survival of antibody-secreting plasma cells. Immunity 45, 60–73 (2016).
Article CAS PubMed PubMed Central Google Scholar
Lam, W. Y. et al. Metabolic and transcriptional modules independently diversify plasma cell lifespan and function. Cell Rep. 24, 2479-2492.e2476 (2018).
Article CAS PubMed PubMed Central Google Scholar
Cantor, J. et al. CD98hc facilitates B cell proliferation and adaptive humoral immunity. Nat. Immunol. 10, 412–419 (2009).
Article CAS PubMed PubMed Central Google Scholar
Rosser, E. C. & Mauri, C. Regulatory B cells: Origin, phenotype, and function. Immunity 42, 607–612 (2015).
Article CAS PubMed Google Scholar
Yanaba, K. et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28, 639–650 (2008).
Article CAS PubMed Google Scholar
Bankoti, R., Gupta, K., Levchenko, A. & Stäger, S. Marginal zone B cells regulate antigen-specific T cell responses during infection. J. Immunol. (Baltimore, Md.: 1950) 188, 3961–3971 (2012).
Article CAS Google Scholar
Gmyrek, G. B., Predki, P., Gershburg, E. & Carr, D. J. J. Noncognate signals drive enhanced effector CD8(+) T cell responses through an IFNAR1-dependent pathway after infection with the prototypic vaccine, 0ΔNLS, against herpes simplex virus 1. J. Virol. 96, e0172421 (2022).
Article PubMed Google Scholar
Yun, H., Rowe, A. M., Lathrop, K. L., Harvey, S. A. & Hendricks, R. L. Reversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis. J. Virol. 88, 7870–7880 (2014).
Article PubMed PubMed Central Google Scholar
Chucair-Elliott, A. J., Zheng, M. & Carr, D. J. Degeneration and regeneration of corneal nerves in response to HSV-1 infection. Invest. Ophthalmol. Vis. Sci. 56, 1097–1107 (2015).
Article CAS PubMed PubMed Central Google Scholar
Filiberti, A., Gmyrek, G. B., Montgomery, M. L., Sallack, R. & Carr, D. J. J. Loss of osteopontin expression reduces HSV-1-induced corneal opacity. Invest. Ophthalmol. Vis. Sci. 61, 24 (2020).
Article CAS PubMed PubMed Central Google Scholar
Rao, P. & Suvas, S. Development of inflammatory hypoxia and prevalence of glycolytic metabolism in progressing herpes stromal keratitis lesions. J. Immunol. (Baltimore, Md.: 1950) 202, 514–526 (2019).
Article CAS Google Scholar
Twardy, B. S., Channappanavar, R. & Suvas, S. Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions. Invest. Ophthalmol. Vis. Sci. 52, 8604–8613 (2011).
Article CAS PubMed PubMed Central Google Scholar
Thomas, J., Gangappa, S., Kanangat, S. & Rouse, B. T. On the essential involvement of neutrophils in the immunopathologic disease: Herpetic stromal keratitis. J. Immunol. (Baltimore, Md.: 1950) 158, 1383–1391 (1997).
CAS Google Scholar
Gimenez, F., Suryawanshi, A. & Rouse, B. T. Pathogenesis of herpes stromal keratitis–a focus on corneal neovascularization. Prog. Retin. Eye Res. 33, 1–9 (2013).
Article PubMed Google Scholar
Wuest, T., Zheng, M., Efstathiou, S., Halford, W. P. & Carr, D. J. The herpes simplex virus-1 transactivator infected cell protein-4 drives VEGF-A dependent neovascularization. PLoS Pathog. 7, e1002278 (2011).
Article CAS PubMed PubMed Central Google Scholar
Hendricks, R. L., Tumpey, T. M. & Finnegan, A. IFN-gamma and IL-2 are protective in the skin but pathologic in the corneas of HSV-1-infected mice. J. Immunol. (Baltimore, Md.: 1950) 149, 3023–3028 (1992).
CAS Google Scholar
Gurung, H. R., Carr, M. M., Bryant, K., Chucair-Elliott, A. J. & Carr, D. J. Fibroblast growth factor-2 drives and maintains progressive corneal neovascularization following HSV-1 infection. Mucosal. Immunol. 11, 172–185 (2018).
Article CAS PubMed Google Scholar
Awasthi, S. et al. Trivalent nucleoside-modified mRNA vaccine yields durable memory B cell protection against genital herpes in preclinical models. J. Clin. Investig. https://doi.org/10.1172/JCI152310 (2021).
Article PubMed PubMed Central Google Scholar
Carr, D. J. J. et al. Distinguishing features of high- and low-dose vaccine against ocular HSV-1 infection correlates with recognition of specific HSV-1-encoded proteins. Immunohorizons 4, 608–626 (2020).
Article CAS PubMed PubMed Central Google Scholar
Cattoretti, G. et al. BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45–53 (1995).
Article CAS PubMed Google Scholar
Muramatsu, M. et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102, 553–563 (2000).
Article CAS PubMed Google Scholar
Liu, Y. J., Grouard, G., de Bouteiller, O. & Banchereau, J. Follicular dendritic cells and germinal centers. Int. Rev. Cytol. 166, 139–179 (1996).
Article CAS PubMed Google Scholar
Fayette, J. et al. Dendritic cells enhance the differentiation of naïve B cells into plasma cells in vitro. Scand. J. Immunol. 48, 563–570 (1998).
Article CAS PubMed Google Scholar
Dubois, B. et al. Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J. Exp. Med. 185, 941–951 (1997).
Article CAS PubMed PubMed Central Google Scholar
Johnson-Léger, C., Hasbold, J., Holman, M. & Klaus, G. G. The effects of IFN-gamma on CD40-mediated activation of B cells from X-linked immunodeficient or normal mice. J. Immunol. (Baltimore, Md.: 1950) 159, 1150–1159 (1997).
Google Scholar
Finkelman, F. D., Katona, I. M., Mosmann, T. R. & Coffman, R. L. IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J. Immunol. (Baltimore, Md.: 1950) 140, 1022–1027 (1988).
CAS Google Scholar
Braun, D., Caramalho, I. & Demengeot, J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 14, 411–419 (2002).
Article CAS PubMed Google Scholar
Gujer, C. et al. IFN-α produced by human plasmacytoid dendritic cells enhances T cell-dependent naïve B cell differentiation. J. Leukoc. Biol. 89, 811–821 (2011).
Article CAS PubMed PubMed Central Google Scholar
Dubois, B. et al. Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes. J. Immunol. (Baltimore, Md.: 1950) 161, 2223–2231 (1998).
CAS Google Scholar
Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529–542 (2014).
Article CAS PubMed PubMed Central Google Scholar
Qi, H. T follicular helper cells in space-time. Nat. Rev. Immunol. 16, 612–625 (2016).
Article CAS PubMed Google Scholar
Rasheed, M. A. et al. Interleukin-21 is a critical cytokine for the generation of virus-specific long-lived plasma cells. J. Virol. 87, 7737–7746 (2013).
Article PubMed PubMed Central Google Scholar
Bessa, J., Kopf, M. & Bachmann, M. F. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J. Immunol. (Baltimore, Md.: 1950) 184, 4615–4619 (2010).
Article CAS Google Scholar
King, I. L., Mohrs, K. & Mohrs, M. A nonredundant role for IL-21 receptor signaling in plasma cell differentiation and protective type 2 immunity against gastrointestinal helminth infection. J. Immunol. (Baltimore, Md.: 1950) 185, 6138–6145 (2010).
Article CAS Google Scholar
Linterman, M. A. et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207, 353–363 (2010).
Article CAS PubMed PubMed Central Google Scholar
Stanfield, B. A., Pahar, B., Chouljenko, V. N., Veazey, R. & Kousoulas, K. G. Vaccination of rhesus macaques with the live-attenuated HSV-1 vaccine VC2 stimulates the proliferation of mucosal T cells and germinal center responses resulting in sustained production of highly neutralizing antibodies. Vaccine 35, 536–543 (2017).
Article CAS PubMed Google Scholar
Yang, K. et al. T cell-derived lymphotoxin is essential for the anti-herpes simplex virus 1 humoral immune response. J. Virol. 92, e00428-18 (2018).
Article CAS PubMed PubMed Central Google Scholar
Akkaya, M. & Pierce, S. K. From zero to sixty and back to zero again: The metabolic life of B cells. Curr. Opin. Immunol. 57, 1–7 (2019).
Article CAS PubMed Google Scholar
Egawa, T. & Bhattacharya, D. Regulation of metabolic supply and demand during B cell activation and subsequent differentiation. Curr. Opin. Immunol. 57, 8–14 (2019).
Article CAS PubMed Google Scholar
Rowe, A. M. et al. Herpes keratitis. Prog Retin Eye Res 32, 88–101 (2013).
Article CAS PubMed Google Scholar
Awasthi, S. et al. Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes. Sci. Immunol. 4, e7083 (2019).
Article Google Scholar
Dhanushkodi, N. R. et al. Antiviral CD19(+)CD27(+) memory B cells are associated with protection from recurrent asymptomatic ocular herpesvirus infection. J. Virol. 96, e0205721 (2022).
Article PubMed Google Scholar
Gmyrek, G. B. et al. HSV-1 0ΔNLS Live-attenuated vaccine protects against ocular HSV-1 infection in the absence of neutralizing antibody in HSV-1 gB T cell receptor-specific transgenic mice. J. Virol. 94, e01000-20 (2020).
Article CAS PubMed PubMed Central Google Scholar
Carr, D. J. J., Berube, A. & Gershburg, E. The durability of vaccine efficacy against ocular HSV-1 infection using ICP0 mutants 0∆NLS and 0∆RING Is lost over time. Pathogens 10, 1470 (2021).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

This work was supported by NIH/NIAID grant R01 AI053108, P20 GM103477, P30 EY021725 as well as an unrestricted grant from Research to Prevent Blindness.

Author information

Authors and Affiliations

Departments of Ophthalmology, The University of Oklahoma Health Sciences Center (OUHSC), 608 Stanton L. Young Blvd, DMEI PA415, Oklahoma City, OK, 73104, USA
Grzegorz B. Gmyrek, Amanda N. Berube & Daniel J. J. Carr
Laboratory for Molecular Biology and Cytometry Research, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
Virginie H. Sjoelund
Microbiology and Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA
Daniel J. J. Carr

Authors

Grzegorz B. Gmyrek
View author publications
You can also search for this author in PubMed Google Scholar
Amanda N. Berube
View author publications
You can also search for this author in PubMed Google Scholar
Virginie H. Sjoelund
View author publications
You can also search for this author in PubMed Google Scholar
Daniel J. J. Carr
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

The study was conceived by G.B.G. and D.J.J.C. The experimental design and experiments were performed by G.B.G., A.N.B., V.H.S., and D.J.J.C. The manuscript was written by G.B.G. and edited by D.J.J.C. All authors reviewed the manuscript.

Corresponding author

Correspondence to Daniel J. J. Carr.

Ethics declarations

Competing interests

D.J.J.C. is an unpaid consultant for the company, Rational Vaccines Inc., that owns the patent rights to the HSV-1 0∆NLS vaccine. All other authors have no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Gmyrek, G.B., Berube, A.N., Sjoelund, V.H. et al. HSV-1 0∆NLS vaccine elicits a robust B lymphocyte response and preserves vision without HSV-1 glycoprotein M or thymidine kinase recognition. Sci Rep 12, 15920 (2022). https://doi.org/10.1038/s41598-022-20180-0

Download citation

Received: 01 June 2022
Accepted: 08 September 2022
Published: 23 September 2022
DOI: https://doi.org/10.1038/s41598-022-20180-0

This article is cited by

Advances in vaccines: revolutionizing disease prevention
- Timir Tripathi
Scientific Reports (2023)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.